UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands		Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2019		$ 172,029	$ 6	$ (33,484)	$ 347,564	$ 181	$ (142,238)
Beginning balance (in shares) at Dec. 31, 2019			63,657	4,145
Increase (Decrease) in Equity
Net loss		(73,528)					(73,528)
Foreign currency translation adjustment		(130)				(130)
Stock issued under employee stock purchase plan		20			20
Stock issued under employee stock purchase plan (in shares)				(25)
Restricted stock granted		338			338
Restricted stock granted (in shares)			2,469
Restricted stock forfeited (in shares)				278
Treasury stock purchased (in shares)				61
Treasury stock purchased		82		$ 82
Stock compensation expense		1,521			1,521
Stock issued in JP3 acquisition		8,538	$ 1		8,537
Stock issued in JP3 acquisition (shares)			11,500
Ending balance at Jun. 30, 2020		108,706	$ 7	$ (33,566)	357,980	51	(215,766)
Ending balance (in shares) at Jun. 30, 2020			77,626	4,459
Beginning balance at Mar. 31, 2020		108,705	$ 6	$ (33,529)	348,375	58	(206,205)
Beginning balance (in shares) at Mar. 31, 2020			64,338	4,395
Increase (Decrease) in Equity
Net loss		(9,561)					(9,561)
Foreign currency translation adjustment		(7)				(7)
Stock issued under employee stock purchase plan		9			9
Stock issued under employee stock purchase plan (in shares)				(12)
Restricted stock granted (in shares)			1,788
Restricted stock forfeited (in shares)				37
Treasury stock purchased (in shares)				39
Treasury stock purchased		37		$ 37
Stock compensation expense		1,059			1,059
Stock issued in JP3 acquisition		8,538	$ 1		8,537
Stock issued in JP3 acquisition (shares)			11,500
Ending balance at Jun. 30, 2020		108,706	$ 7	$ (33,566)	357,980	51	(215,766)
Ending balance (in shares) at Jun. 30, 2020			77,626	4,459
Beginning balance at Dec. 31, 2020		$ 47,171	$ 8	$ (33,851)	359,721	(19)	(278,688)
Beginning balance (in shares) at Dec. 31, 2020			78,669	5,581
Increase (Decrease) in Equity
Other (shares)		600
Ending balance at Mar. 31, 2021		$ 39,631	$ 8	$ (33,956)	360,537	30	(286,988)
Ending balance (in shares) at Mar. 31, 2021			78,276	5,573
Beginning balance at Dec. 31, 2020		47,171	$ 8	$ (33,851)	359,721	(19)	(278,688)
Beginning balance (in shares) at Dec. 31, 2020			78,669	5,581
Increase (Decrease) in Equity
Net loss		(14,846)					(14,846)
Foreign currency translation adjustment		32				32
Stock issued under employee stock purchase plan		(177)		$ (130)	(47)
Stock issued under employee stock purchase plan (in shares)				(84)
Restricted stock granted (in shares)			1,684
Restricted stock forfeited		64		$ 64
Restricted stock forfeited (in shares)			(133)	30
Stock compensation expense		1,750			1,750
Excess tax benefit related to share-based awards (in shares)				101
Excess tax benefit related to share-based awards		(100)		$ (100)
Other (shares)	[1]		(613)
Stock issued in JP3 acquisition		0
Ending balance at Jun. 30, 2021		33,894	$ 8	$ (34,017)	361,424	13	(293,534)
Ending balance (in shares) at Jun. 30, 2021			79,607	5,628
Beginning balance at Mar. 31, 2021		39,631	$ 8	$ (33,956)	360,537	30	(286,988)
Beginning balance (in shares) at Mar. 31, 2021			78,276	5,573
Increase (Decrease) in Equity
Net loss		(6,546)					(6,546)
Foreign currency translation adjustment		(17)				(17)
Stock issued under employee stock purchase plan		(40)		$ (38)	(2)
Stock issued under employee stock purchase plan (in shares)				(26)
Restricted stock granted		(7)			(7)
Restricted stock granted (in shares)			1,465
Restricted stock forfeited		0		$ 54	(54)
Restricted stock forfeited (in shares)			(134)	25
Stock compensation expense		969			969
Excess tax benefit related to share-based awards (in shares)				56
Excess tax benefit related to share-based awards		(96)		$ (77)	(19)
Ending balance at Jun. 30, 2021		$ 33,894	$ 8	$ (34,017)	$ 361,424	$ 13	$ (293,534)
Ending balance (in shares) at Jun. 30, 2021			79,607	5,628

[1] See Note 14, “Stockholders’ Equity” for further discussion.